A study conducted by researchers at the Center for Cell-Based Therapy (CTC) highlights key proteins and signaling pathways ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

CP-A cells have been discovered that increase belly fat production with age, linking waist size to metabolic and cardiovascular risks.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

B-cell lymphomas make up most (about 85%) of the non-Hodgkin lymphomas (NHL) in the United States. These types of lymphomas start in early forms of B lymphocytes (B cells). The most common types of ...

Objective The role of neutrophils in driving pathogenic B cell responses in SLE is not fully understood. In this study, we explored the link between immune complex (IC)–driven neutrophil activation, ...

MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity, a study found.

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.